Does Forteo Build Bone?
Yes, Forteo (teriparatide) builds bone by stimulating new bone formation. It is a synthetic form of parathyroid hormone that activates osteoblasts, the cells responsible for creating bone tissue. Clinical trials showed it increases bone mineral density (BMD) at the spine by 9-13% and at the hip by 2-4% after 21 months of daily subcutaneous injections.[1][2]
How Does Forteo Work Mechanically?
Forteo mimics the body's parathyroid hormone, which regulates calcium and bone metabolism. Unlike bisphosphonates that mainly slow bone breakdown, Forteo directly promotes bone-building through intermittent dosing. This anabolic effect leads to thicker, stronger bone structure, particularly in trabecular bone like the spine.[1][3]
Evidence from Key Clinical Studies
The Fracture Prevention Trial, a pivotal study of 1,637 postmenopausal women with osteoporosis, found Forteo reduced vertebral fractures by 65% and non-vertebral fractures by 53% over 21 months, linked to BMD gains.[2] Follow-up data confirmed sustained benefits even after switching to antiresorptive therapy.[4] It's FDA-approved for high-risk osteoporosis patients, including those with prior fractures.
Who Qualifies for Forteo Treatment?
Prescribed for postmenopausal women, men with osteoporosis, or glucocorticoid-induced cases at high fracture risk. Limited to 2 years lifetime use due to osteosarcoma risk in animal studies. Not for patients with Paget's disease, bone metastases, or hypercalcemia.[1]
What Results Do Patients Typically See?
Users report BMD increases within 6-12 months, with peak effects by 18-24 months. Real-world data aligns with trials: spine BMD rises 10-13%, femoral neck 2-4%. Bone turnover markers elevate early, confirming active formation.[3][5] Effects reverse if treatment stops without follow-up therapy.
Common Side Effects and Risks
Dizziness, leg cramps, nausea occur in 5-10% of users. Black-box warning for osteosarcoma risk (rare in humans). Hypercalcemia in 1-2%; monitor kidney function. Not for children or those with radiation history.[1][2]
How Does Forteo Compare to Other Osteoporosis Drugs?
| Drug Class | Example | Main Action | BMD Gain (Spine, ~1-2 yrs) | Fracture Reduction |
|------------|---------|-------------|-----------------------------|-------------------|
| Anabolic | Forteo | Builds bone | 9-13% | Vertebral: 65% |
| Antiresorptive | Fosamax (alendronate) | Slows breakdown | 5-8% | Vertebral: 47% |
| Antiresorptive | Prolia (denosumab) | Slows breakdown | 7-9% | Vertebral: 68% |
| Anabolic | Tymlos (abaloparatide) | Builds bone (similar mechanism) | 8-13% | Vertebral: 86% |
Forteo outperforms antiresorptives in rapid BMD gains but requires daily injections vs. weekly pills. Tymlos is a close competitor with potentially fewer side effects.[3][6]
Cost and Access Factors
Costs $2,500-$4,000 monthly without insurance; patient assistance programs available via manufacturer. Injectable pen format simplifies use.[7]
When Does Forteo's Patent Expire?
Core U.S. patents expired in 2019, but formulation patents extend to 2025-2030. No biosimilars approved yet; check DrugPatentWatch.com for litigation updates.[8]
Sources
[1]: Forteo Prescribing Information (FDA)
[2]: NEJM: Teriparatide Fracture Trial (2001)
[3]: Endocrine Reviews: PTH Anabolics (2014)
[4]: JAMA: Post-Forteo Effects (2005)
[5]: JBMR: Real-World BMD Data (2018)
[6]: Head-to-Head: Forteo vs Tymlos (Lancet, 2016)
[7]: GoodRx Pricing Data
[8]: DrugPatentWatch.com: Forteo Patents